bbb

1. Malignant
40%Non-
Malignant
60%
Brain and CNS cancer
> 70,000
New Cases in 2013

2. Malignant
40%Non-
Malignant
60%
Brain and CNS cancer

3. Surgery
Radiation Therapy Chemotherapy
Targeted Therapy
$4.5 Billion

4. Treatment
and
Diagnostics
53%
Other
47%
$150 Millions
Brain and CNS Cancer Research

5. 60-70 %
Overall Cancer Treatment Failure
Over 14,000 deaths will occur a malignant Brain or CNS tumor
Five year survival rate following therapy remains at 33%
Overall mortality rates have minimally changed over the past 20 years

6. TREATMENTS FAIL
BECAUSE THERE IS
NO EFFICIENT
TREATMENT
MONITORING
METHODS

8. Physically Altered Cancer Cells
Viable Cancer Cell
Ultrasound

9. Significantly Reduce
wait-times
to determine cancer
tumour response to
treatment
Increase productivity
and efficiency in new
drug development
Enables rapid
treatment response
monitoring for
cancer patients
Enable
Pharmaceutical
companies to
rapidly identify
promising drugs
Enable Oncologists
to switch treatment
strategy and make
treatment more
adaptive to patient
response.
Drug-
discovery
market
Clinical
market

10. Significantly
Reduce wait-times
to determine
cancer tumour
response to
treatment
Increase productivity
and efficiency in new
drug development
Enable
Pharmaceutical
companies to
rapidly identify
promising drugs
Decrease Costs Increase Productivity
Cranial Window or
Transcranial Imaging
Minimize Histology
Minimize Animals Used
Minimally Invasive
Rapid Treatment
Assessment
Pre-Clinical Patent
No Regulatory Hurdles
Ultrasound Inexpensive
and Globally Available

11. In the Clinic …
Transcranial and/or Intraoperative Ultrasound
Tumour Characterization and Treatment Monitoring